Dossier assessment
Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
-
Dossier assessment
Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Press releases
Pembrolizumab in advanced melanoma: added benefit for certain patients
Additional information
Federal Joint Committee (G-BA)
2016-02-04 A G-BA decision was published.
Project details
- Project no.
- A15-33
- Commission
- Commission awarded on 17.08.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (endometrial carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (bile cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (melanoma, advanced) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (melanoma, adjuvant) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed